Presentation by Dr. Kevin Garey at the Peggy Lillis Foundation Inaugural CDI Scientific Symposium with Phase 2 Clinical Trial Update
Presentation at ICDS Conference, September 2024, Microbiome Results from the phase 2, randomized, double-blind study of ibezapolstat compared with vancomycin for the treatment of Clostridioides difficileinfection
Smits presentation at ICDS Conference, September 2024 “Structure of the replicative polymerase PolC in complex with the anti-CDI agent ibezapolstat and a related inhibitor.”
Presentation by Kevin Garey, PharmD, MS, FIDSA, Professor and Chair, University of Houston College of Pharmacy, at ESCMID (April 2024) entitled “ Efficacy and safety of ibezapolstat compared with vancomycin for the treatment of Clostridioides difficile infection: a phase 2, randomized, double-blind study
Golf Coast Consortia AMR Conference Presentation of Ph2b Comparative Microbiology and Microbiome Data, by Dr. Kevin Garey, et. al., January 2024
ID Week Presentation Dr. Kevin Garey “Gram Positive Selective Spectrum Activity of Ibezapolstat October 2023
